Novel regulators of cellular events in prostate cancer tissue and stroma

Poster Session 04

Friday 15 March
09:00 - 10:30

Location: Green Area, Room 5
Chairs: D. Albino, Bellinzona (CH)
M. Puhr, Innsbruck (AT)
To be confirmed

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

43

The bone microenvironment drives upregulation of the pentose phosphate pathway in prostate cancer, improving antioxidant properties

By: Whitburn J. 1, Rao S.R. 1, Tabata S 2, Hirayama A. 2, Soga T. 2, Hamdy F.C. 1, Edwards C.M. 1
1University of Oxford, Nuffield Dept. of Surgical Sciences, Oxford, United Kingdom,
2Keio University, Institute for Advanced Biosciences, Tsuruoka, Japan

Aims and objectives of this presentation

44

Xenobiotic metabolism of abiraterone acetate and glucocorticoids by the gut microbiota

By: Abdur-Rashid K. 1, Nair S.M. 2, Chanyi R. 1, Chin J. 2, Burton J. 1
1University of Western Ontario, Dept. of Microbiology and Immunology, London, Canada,
2London Health Sciences Centre, Division of Urology, London, Canada

Aims and objectives of this presentation

45

A preclinical model to assess the interaction between patient-derived 3D microtumors and tumor infiltrating immune cells in prostate cancer

By: Erne E. 1, Stahl R. 1, Bodenhoefer M. 2, Anderle N. 2, Yuez S. 2, Stenzl A. 1, Schmees C. 2, Todenhoefer T. 1
1University Hospital Tuebingen, Dept. of Urology, Tuebingen, Germany,
2Natural and Medical Science Institute, University of Tuebingen, Dept. of Tumorbiology, Reutlingen, Germany

Aims and objectives of this presentation

46

Loss of miR-21 delays Myc-driven prostate cancer progression in the Hi-Myc transgenic mouse model
HSP70/STUB1 complex regulates androgen receptor variants through proteostasis and confers enzalutamide and abiraterone resistance in lethal prostate cancer

University of California Davis, Dept. of Urology, Sacramento, United States of America

Long noncoding RNA CRAT1 inhibits castration-resistance of prostate cancer via inhibiting androgen receptor protein translation

By: Xu C., Peng G., Ruihui X., Ming H., Qianghua Z., Jingtong Z., Jian H., Tianxin L.
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Dept. of Urology, Guangzhou, China

EphA2 ligand independent activation underpins PTEN related metastatic migration and poor outcome in prostate cancer

1University of Manchester, Genito Urinary Cancer Research Group, Manchester, United Kingdom, 2The Christie, Dept. of Surgery, Manchester, United Kingdom

The role of SPOP & BRCA-1 in the regulation of estrogenic activity in prostate stem cells

By: Greenwald D., Hu D-P., Hu W-Y., Prins G.S.
University of Illinois at Chicago, Dept. of Urology, Chicago, United States of America

Tumor suppressor REIC/Dkk-3 and its co-chaperone SGTA: Their interaction and role to control castration-resistant prostate cancer by the release from androgen...
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>51</td>
<td>independence and malignancy</td>
<td>Sadahira T., Maruyama Y., Mitsui Y., Wada K., Edamura K., Kobayashi Y., Araki M., Watanabe M., Watanabe T., Nasu Y.</td>
<td>Okayama University Graduate School of Medicine, Dept. of Urology, Okayama, Japan</td>
</tr>
<tr>
<td>52</td>
<td>miR-424 secreted in extracellular vesicles/exosomes promotes prostate tumorigenesis</td>
<td>Albino D., Falcione M., Shinde D.S., Civenni G., Merulla J., Catapano C.V., Carbone G.M.</td>
<td>Institute of Oncology Research (IOR), Dept. of Experimental Therapeutics &amp; Prostate Cancer Biology, Bellinzona, Switzerland</td>
</tr>
<tr>
<td>54</td>
<td>Follicle-stimulating hormone is responsible for androgen deprivation therapy associated atherosclerosis by exaggerating endothelial inflammation</td>
<td>Wang Q., Zhou J., Yao W., Xu T.</td>
<td>1Peking University People’s Hospital, Dept. of Urology, Beijing, China, 2Peking University, Dept. of Physiology and Pathophysiology, Beijing, China</td>
</tr>
<tr>
<td>55</td>
<td>GPRC5A facilitates cell proliferation and bone metastasis of prostate cancer</td>
<td>Sawada Y., Kikugawa T., Iio H., Yanagihara Y., Saeki N., Sakakibara I., Gyölfy B., Kishida T., Miyagi Y., Saika T., Imai Y.</td>
<td>1Ehime University Graduate School of Medicine, Dept. of Urology, Toon, Japan, 2Ehime University, Division of Laboratory Animal Research, Advanced Research Support Center,</td>
</tr>
</tbody>
</table>
Toon, Japan, 3Ehime University, Division of Integrative Pathophysiology, Proteo-Science Center, Toon, Japan, 4The University of Tokyo, Research Center for Advanced Science and Technology, Tokyo, Japan, 5Hungarian Academy of Sciences, MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Budapest, Hungary, 6Kanagawa Cancer Center, Division of Urology, Kanagawa, Japan, 7Kanagawa Cancer Center Research Institute, Molecular Pathology and Genetics Division, Kanagawa, Japan

### Aims and objectives of this presentation

#### 56

**Generation of prostate basal stem cell lines from transgenic mice - proof of principle of inducible ex vivo gene deletion**

By: Höfner T. 1, Klein C. 2, Medyouf H. 3, Sprick M. 2, Haferkamp A. 1

1University Hospital Mainz, Dept. of Urology, Mainz, Germany, 2HI-STEM gGmbH, Heidelberg Institute for Stem Cell Research and Experimental Medicine, Heidelberg, Germany, 3Georg-Speyer-Haus, Institute for Tumorbiology and Experimental Therapy, Frankfurt, Germany

### Aims and objectives of this presentation

56

#### 57

**Fibroblast-secreted exosomes in prostate cancer**

By: Kessler J., Theobald L., Baumgart S., Stöckle M., Junker K., Linxweiler J.

Saarland University, Dept. of Urology, Homburg, Germany

### Aims and objectives of this presentation

57